Securities code: 300138 securities abbreviation: Chenguang Biotech Group Co.Ltd(300138) Announcement No.: 2022-012 Chenguang Biotech Group Co.Ltd(300138)
Announcement on the resolutions of the 25th meeting of the 4th board of supervisors
The company and all members of the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
The board of supervisors of Chenguang Biotech Group Co.Ltd(300138) (hereinafter referred to as "the company") sent the notice of the 25th meeting of the fourth session of the board of supervisors to all supervisors by hand and e-mail on February 14, 2022. The meeting was held in the company's conference room on February 19, 2022 in a combination of on-site and communication. The meeting was presided over by Mr. Gao Wei, chairman of the board of supervisors. There were three supervisors who should attend the meeting and three supervisors who actually attended the meeting (supervisor Wang Shaohua participated by means of communication). The meeting was held in accordance with the company law, the articles of association and other relevant provisions. The following proposals were deliberated and adopted after the study and discussion of the participating supervisors:
1、 The proposal on using some idle raised funds to temporarily supplement working capital was deliberated and adopted. In order to improve the use efficiency of raised funds, on the premise of ensuring the capital demand of investment projects with raised funds, The company plans to temporarily supplement the working capital required for daily operation with the raised capital of no more than 325 million yuan temporarily idle in the "integrated natural plant extraction project (phase I)" for a period of no more than 12 months. The voting procedures and implementation of the above matters comply with the relevant laws, regulations, normative documents and the articles of association of the company, such as the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 - standardized operation of listed companies on GEM, etc, There is no situation that changing the investment direction of the raised funds in a disguised form will damage the rights and interests of the company and all shareholders (especially small and medium-sized shareholders), which is conducive to improving the use efficiency of the raised funds. It is agreed that the company will use the temporarily idle raised funds of no more than 325 million yuan to temporarily supplement the working capital for a period of no more than 12 months.
Voting result: three affirmative votes; No votes; No abstentions.
It is hereby announced
Chenguang Biotech Group Co.Ltd(300138) board of supervisors
February 21, 2022
